US Diabetes Market

United States Diabetes Market Size and Share:

The United States diabetes market size reached USD 30.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 39.6 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The market is driven by strong growth fueled by increasing prevalence of diabetes, rising obesity levels, and growing aging population. Market growth is being propelled by advancements in insulin delivery devices, continuous glucose monitoring systems, and digital health platforms. Supportive reimbursement policies and increased awareness regarding early detection also contribute to the growth. Furthermore, advancements in personalized medicine and non-invasive monitoring products are major opportunities. But pricing pressures and regulatory issues could slightly hold back swift market growth in the next few years.

Diabetes, also referred to as diabetes mellitus, is a group of metabolic diseases in which a person suffers from high blood glucose. This can be either caused by the inappropriate response to insulin by the body, inadequate insulin production. If not monitored properly, diabetes can be fatal and cause serious health complications such as heart diseases, stroke, amputation, blindness and kidney diseases. According to the Centers for Disease Control and Prevention (CDC), more than 30 million adults have been diagnosed with diabetes or prediabetes in the United States. In 2018, the United States represented the third largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels. Apart from this, physical inactivity and unhealthy lifestyle have further contributed to the escalating diabetic population.

The increasing diabetes prevalence has led the Government of US to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior amongst the citizens. In line with this, there has been a rise in diabetes diagnosis, monitoring and drug treatment rates. Moreover, the FDA has approved the production of Basaglar and Admelog, the biosimilar versions of insulin glargine and lispro. Several other diabetes drugs are also expected to gain approval in the coming years, which will further drive the growth of the market. Apart from this, rapid technological advancements have enabled the manufacturers to develop continuous glucose monitoring (CGM) device. It allows type-2 diabetes patients to check their blood periodically with the help of testing strips and easily monitor their blood sugar levels.

United States Diabetes Market Trends:

Rising Adoption of Continuous Glucose Monitoring (CGM) Devices

The increasing trend towards Continuous Glucose Monitoring (CGM) devices is revolutionizing diabetes management in the U.S. market. The systems enable real-time measurement of blood glucose levels, providing ease of use and improved glycemic control over finger-prick methods. Demand for wearable, easy-to-use health technology among consumers is promoting the adoption of CGM, particularly with newer models that seamlessly connect with smartphones and digital health platforms. Widespread availability of prescription-free CGMs is expanding access among pre-diabetics and non-insulin users. The technical improvements in sensor precision, battery duration, and wireless connectivity also render CGM devices more appealing to both patients and clinicians. Home-based and remote monitoring solutions also favor CGM's growing popularity, making these devices a key part of proactive and patient-centric diabetes management plans.

Technological Advancements in Insulin Delivery Devices

The American diabetes market is seeing tremendous innovation in insulin delivery technology, driven by the need to enhance convenience, safety, and precision. Conventional insulin syringes and pens are slowly being replaced by smart insulin pens and adaptive insulin pumps for ease of use and real-time adjustment of doses. These new devices are becoming more integrated with digital platforms, providing dose tracking, reminders, and sharing of data with healthcare providers for remote monitoring. Rising focus on personalized treatment plans is driving demand for insulin pumps with automatic adjustment of delivery according to blood glucose levels. Furthermore, patient preference for discreet, portable, and user-friendly products is driving product development. These innovations are minimizing user error, increasing compliance, and overall quality of diabetes care, driving the development of next-generation insulin therapy solutions.

Expansion of Novel Diabetes Drug Therapies

The landscape of diabetes drug therapy in the United States is changing as pharmaceutical companies place emphasis on coming up with more effective and safer drugs. A trend toward drugs that provide both blood glucose control and benefits of cardiovascular and renal protection has been observed. Incretin-based therapy, dual-action agents, and new oral drugs are being introduced into the marketplace, increasing treatment options for type 1 and type 2 diabetes. Concurrently, increased focus on patient-centered medicine is spurring the creation of tailored drug regimens to reduce side effects and enhance compliance. Concurrently, biosimilar insulin availability is offering cost-saving options, enhancing accessibility for a larger base of patients. This broadening and diversifying drug pipeline is poised to redefine the therapeutic landscape, bringing promise of enhanced long-term disease management and overall patient outcomes.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the United States diabetes market report, along with forecasts for the period 2025-2033. Our report has categorized the market based on segment.

Breakup by Segment:

• Insulin
• Oral Antidiabetics

At present, insulin exhibits a clear dominance over oral antidiabetics on account of the convenience and efficacy of insulin delivery devices. Amongst the various product types, long acting insulin represents the largest insulin class in the US, whereas DPP-IV inhibitors are the leading oral-antidiabetics class in the nation.

Competitive Landscape:

The report has examined the competitive landscape of the market and finds that it is highly fragmented in nature with the presence of numerous small and large manufacturers. Some of the key players operating in the market are:

• Sanofi US Services Inc.
• Novo Nordisk Inc.
• Eli Lilly and Company
• Merck & Co. Inc.
• Zeneca Holdings Inc.
• Johnson & Johnson

Latest News and Developments:

• In June 2025, Medtronic announced "MiniMed" as the official name for its planned new diabetes company, following its upcoming separation. The name revives the brand's legacy from before its 2001 Medtronic acquisition, reflecting over 40 years of innovation in diabetes care. MiniMed will focus on advancing technology to make diabetes management more predictable and less burdensome, continuing its mission to improve the daily lives of people living with diabetes worldwide.
• In April 2025, Cardinal Health has completed its acquisition of Advanced Diabetes Supply Group (ADSG), a major U.S. provider of direct-to-patient diabetes medical supplies. This move supports Cardinal Health at-Home Solutions’ strategy to expand its reach and enhance diabetes care offerings, including continuous glucose monitors (CGMs). The acquisition strengthens Cardinal Health’s position in the growing diabetes market by integrating ADSG’s expertise and patient services into its home healthcare business.
• In March 2025, Tandem Diabetes Care launched its new Control-IQ+ automated insulin delivery (AID) technology in the U.S., expanding access to individuals aged 2 and older with type 1 diabetes and adults with type 2 diabetes. Compatible with the t:slim X2 pump and Tandem Mobi System, Control-IQ+ offers enhanced personalization and flexibility. New pumps will feature the technology, while existing users can upgrade remotely at no cost.

What we have achieved in this report:

Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:

Focus of the Analysis:

• Historical, current and future prevalence of diabetes in the US
• Impact of COVID-19 on the diabetes market in the United States
• Historical, current and future prevalence of type-1 and type-2 diabetes in the US
• Historical, current and future prevalence of diabetes in the urban and rural regions in the US
• Historical, current and future prevalence of diabetes among males and females in the US
• Historical, current and future prevalence of diabetes among various age groups in the US
• Historical, current and future diagnosis rates for diabetes in the US
• Historical, current and future drug treatment rates for diabetes in the US
   

Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

• Performance of the Oral Antidiabetics market in the US
• Performance of key classes
• Performance of key players
• Market outlook
   

Comprehensive situation analysis of the US Insulin market and its dynamics:

Focus of the Analysis:

• Performance of the Insulin market in the US
• Performance of key classes
• Performance of key players
• Market outlook